As of June 10, 2025, Ianthus Capital Holdings Inc (IAN.CN) reports a EV/EBITDA of 5.39.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Ianthus Capital Holdings Inc's EV/EBITDA to Peers
To better understand Ianthus Capital Holdings Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Ianthus Capital Holdings Inc (IAN.CN) | 5.39 |
| M2bio Sciences Inc (WUHN) | 38.76 |
| Harrow Health Inc (HROW) | 36.44 |
| Alimera Sciences Inc (ALIM) | 31.17 |
| Cumberland Pharmaceuticals Inc (CPIX) | 24.31 |
| Recro Pharma Inc (REPH) | 15.42 |
Compared to its competitors, Ianthus Capital Holdings Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.